PDF) Clinical outcomes in patients with chronic lymphocytic leukemia with disease progression on ibrutinib
Pretreatment with ibrutinib reduces cytokine secretion and limits the risk of obinutuzumab-induced infusion-related reactions in patients with CLL: analysis from the iLLUMINATE study | springermedizin.de
Long-Term Studies Assessing Outcomes of Ibrutinib Therapy in Patients With Del(11q) Chronic Lymphocytic Leukemia
Pretreatment with ibrutinib reduces cytokine secretion and limits the risk of obinutuzumab-induced infusion-related reactions in patients with CLL: analysis from the iLLUMINATE study | springermedizin.de
PDF) Clinical outcomes in patients with chronic lymphocytic leukemia with disease progression on ibrutinib
Cancers | Free Full-Text | The Role of Bruton’s Kinase Inhibitors in Chronic Lymphocytic Leukemia: Current Status and Future Directions
ABBVIE: IMBRUVICA® (ibrutinib) Plus GAZYVA® (obinutuzumab) Phase 3 iLLUMINATE Trial for First-Line Therapy of Chronic Lymphocytic Leukemia (CLL) Patients Met Primary Endpoint | American Pharmacy News
JANSSEN | Business Wire
On the architecture of translational research designed to control chronic lymphocytic leukemia
Long-Term Studies Assessing Outcomes of Ibrutinib Therapy in Patients With Del(11q) Chronic Lymphocytic Leukemia - ScienceDirect
régi Átlátni Szellőztetés pcyc 1130 illuminate trial presentation overall survival nacionalizmus körte Kábító
régi Átlátni Szellőztetés pcyc 1130 illuminate trial presentation overall survival nacionalizmus körte Kábító
PDF) Clinical outcomes in patients with chronic lymphocytic leukemia with disease progression on ibrutinib
New Paradigms in the Treatment of Acute Lymphoblastic Leukemia, Chronic Lymphocytic Leukemia, Acute Myeloid Leukemia and Chronic
First-line treatment of chronic lymphocytic leukemia with ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab: final analysis of the randomized, phase III iLLUMINATE trial | Haematologica
The role of MRD in CLL
PCYC 2014.12.31 - 10-K
régi Átlátni Szellőztetés pcyc 1130 illuminate trial presentation overall survival nacionalizmus körte Kábító
régi Átlátni Szellőztetés pcyc 1130 illuminate trial presentation overall survival nacionalizmus körte Kábító
Minimal Residual Disease in Chronic Lymphocytic Leukemia: A New Goal?
Cancer patient survival can be parametrized to improve trial precision and reveal time-dependent therapeutic effects | Nature Communications
PDF) Single-agent ibrutinib in RESONATE-2™ and RESONATE™ versus treatments in the real-world PHEDRA databases for patients with chronic lymphocytic leukemia
PDF) Long‐term efficacy of first‐line ibrutinib treatment for chronic lymphocytic leukaemia in patients with TP53 aberrations: a pooled analysis from four clinical trials
1 Media Inquiries: Satu Glawe Phone: +49-172-294-6264 Bernadette King Phone: 1-215-778-3027 Investor Relations: Christopher DelO
New Paradigms in the Treatment of Acute Lymphoblastic Leukemia, Chronic Lymphocytic Leukemia, Acute Myeloid Leukemia and Chronic
Long-Term Studies Assessing Outcomes of Ibrutinib Therapy in Patients With Del(11q) Chronic Lymphocytic Leukemia - ScienceDirect
Evolving Strategies for the Treatment of Chronic Lymphocytic Leukemia in the Upfront Setting | SpringerLink
